Arvinas Announces Participation in Key Investor Conferences
Arvinas, Inc. (NASDAQ: ARVN), a pioneering biotechnology company specializing in targeted protein degradation, is gearing up for significant engagement at two prominent investor conferences. These conferences are pivotal opportunities for the company to showcase its innovations in drug development and connect with potential investors.
Guggenheim Securities Healthcare Innovation Conference
Scheduled for November 13, the Guggenheim Securities Healthcare Innovation Conference will feature presentations by leading members of Arvinas' management team. Both Noah Berkowitz, MD, Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will be actively participating in a fireside chat. This interactive session aims to provide insights into the cutting-edge developments at Arvinas and the significant impact their therapies may offer to patients.
Live Webcast Details
Investors interested in the session can access a live audio webcast on Arvinas' website in the Events and Presentations section. This webcast will offer a platform for stakeholders to engage with the company’s vision for the future while learning more about its drug development pipeline.
Jefferies London Healthcare Conference
Following the Guggenheim conference, Arvinas will also participate in the Jefferies London Healthcare Conference on November 19. During this event, Noah Berkowitz, along with Andrew Saik, Chief Financial Officer, will present another fireside chat focused on the company’s strategic initiatives and advancements in clinical trials.
Opportunities for Investor Insight
This conference too promises to be insightful for investors, showcasing the innovative paths Arvinas is pursuing to bring significant therapeutic advances in protein degradation to market.
About Arvinas
Arvinas is not just another biotechnology company; it is at the forefront of creating new classes of therapies designed to tackle some of the most serious diseases. With its proprietary PROTAC (PROteolysis Targeting Chimera) technology, Arvinas is transforming the way medical science approaches drug development. The goal is straightforward: use the body’s innate mechanisms to degrade specific proteins that cause disease, paving the way for effective and targeted treatments.
Clinical Development Pipeline
Among its leading investigational drugs, Arvinas is advancing vepdegestrant, aimed at the estrogen receptor for patients with persistent ER+/HER2- breast cancer. Another key drug in their pipeline is ARV-393, designed to target BCL6 to provide solutions for relapsed or refractory non-Hodgkin lymphoma. Additionally, ARV-102 targets LRRK2, focusing on neurodegenerative disorders, marking significant steps forward in therapeutic options for various challenging conditions.
Why Attend the Conferences?
These conferences represent more than just presentations; they are opportunities for deeper understanding of how Arvinas is actively changing the landscape of biotechnology. For investors, these engagements provide crucial insights into the company’s operational strategies and future directions.
Engagement with Stakeholders
Arvinas remains committed to transparency and engagement with its shareholders, offering avenues to ask questions and gain clarity on its project goals and advancements. Such interactions can be invaluable for investors looking to understand the potential impacts of groundbreaking biotechnology on health outcomes.
Contact Information
For further inquiries, Arvinas has made it easy to connect with its investor relations team:
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
Frequently Asked Questions
What are the key upcoming events for Arvinas?
Arvinas will participate in the Guggenheim Securities Healthcare Innovation Conference and the Jefferies London Healthcare Conference in November.
Who will represent Arvinas at these conferences?
Noah Berkowitz, MD, Ph.D., and Randy Teel, Ph.D., will be present at Guggenheim, while Noah Berkowitz and Andrew Saik will represent Arvinas at Jefferies.
What innovations is Arvinas focusing on?
Arvinas is concentrating on targeted protein degradation therapies, utilizing its PROTAC technology to develop new classes of drugs.
How can investors access the presentations?
Investors can access the live webcasts of the presentations on the Arvinas website under the Events and Presentations section.
What is the significance of Arvinas' drug pipeline?
The pipeline includes innovative drugs aimed at treating debilitating diseases, such as breast cancer and non-Hodgkin lymphoma, which could significantly improve patient care.
